MedTrace Logo

A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

NCT00301535 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-05-16

No results posted yet for this study

Summary

The purpose of this study is to determine if Hemopure® will enhance tissue preservation during Cardiopulmonary Bypass surgery.

Conditions

Interventions

DRUG

HBOC-201 (hemoglobin glutamer-250 bovine)

HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL

Sponsors & Collaborators

  • Biopure Corporation

    lead INDUSTRY

Principal Investigators

  • A. Gerson Greenburg, MD, Ph.D · Biopure Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • Greece
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00301535 on ClinicalTrials.gov